Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | VNN1 | O95497 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | GALR2 | O43603 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28046979 | 0.87 | PTGS2 (0.52) | MAPTSMN1; SMN2PTGS2TP53VNN1 | |
| SCHEMBL28046990 | 0.84 | PTGS2 (0.49) | MAPTSMN1; SMN2PTGS2TP53VNN1 | |
| SCHEMBL24460958 | 0.83 | CLK4 (0.53) | MAPTPTGS2CLK4HRH4PTGDR | |
| SCHEMBL2087964 | 0.83 | ACP1 (0.64) | MAPTSMN1; SMN2PTGS2TP53ACP1 | |
| SCHEMBL7168206 | 0.81 | CLK4 (0.51) | MAPTSMN1; SMN2CLK4HRH4PTGDR | |
| SCHEMBL24272809 | 0.81 | CLK1 (0.52) | MAPTSMN1; SMN2PTGS2TP53CLK4 | |
| SCHEMBL115440 | 0.80 | CLK4 (0.50) | MAPTCLK4HRH4PTGDR | |
| SCHEMBL20637881 | 0.80 | CLK4 (0.50) | MAPTSMN1; SMN2PTGS2TP53VNN1 | |
| SCHEMBL29880059 | 0.80 | CLK4 (0.50) | MAPTSMN1; SMN2PTGS2TP53VNN1 | |
| SCHEMBL2448924 | 0.79 | USP1 (0.55) | MAPTSMN1; SMN2PTGS2TP53VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542552-B1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-15 | — | — | EP | disclosed |
| US-9718820-B2 | Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-01 | — | — | US | disclosed |
| US-20160304518-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-20 | — | — | US | disclosed |
| US-9409915-B2 | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-09 | — | — | US | disclosed |
| US-20150158875-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-11 | — | — | US | disclosed |
| US-9023846-B2 | Substituted AZA-bicyclic imidazole derivatives useful as TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-05 | — | — | US | disclosed |
| US-20140155395-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-05 | — | — | US | disclosed |
| US-8680098-B2 | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-25 | — | — | US | disclosed |
| EP-2542552-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011109587-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-09 | — | — | WO | disclosed |
| US-20110218197-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304518-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | MAPT 2093/4885SMN1; SMN2 2260/4885PTGS2 1075/4885 |
| US-20150158875-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | MAPT 2093/4885SMN1; SMN2 2260/4885PTGS2 1075/4885 |
| US-20140155395-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | MAPT 2093/4885SMN1; SMN2 2260/4885PTGS2 1075/4885 |
| US-20110218197-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | MAPT 2093/4885SMN1; SMN2 2260/4885PTGS2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.